Nateglinide Chemische Eigenschaften,Einsatz,Produktion Methoden
R-S?tze Betriebsanweisung:
R22:Gesundheitssch?dlich beim Verschlucken.
S-S?tze Betriebsanweisung:
S24/25:Berührung mit den Augen und der Haut vermeiden.
S36:DE: Bei der Arbeit geeignete Schutzkleidung tragen.
Beschreibung
Nateglinide is a N-acylated D-phenylalanine marketed in
Japan as novel orally active insulinotropic agent for the treatment of type-2
diabetes mellitus. It belongs to the class of nonsulfonylureas and shows some
structural similarity to repaglinide, the only other representative in this family. In
single pancreatic beta-cells isolated from rats, Nateglinide was found to
specifically block the ATP-sensitive K+ channel resulting in an increase in
intracellular calcium concentration. This primary action would underlie the
mechanism by which Nateglinide markedly stimulates or potentiates, depending
on glucose concentrations, insulin secretion from pancreatic beta-cells. Clinical
studies demonstrated a good safety profile with a low potential for
hypoglycemia. The pharmacokinetic profile was consistent with the changes of
the blood glucose and plasma insulin level. Interestingly, Nateglinide exerts a
rapid onset and short duration of action due to a rapid absorption and clearance.
Unlike other similar agents, Nateglinide suppresses postprandial glucose
elevations.
Chemische Eigenschaften
Cyrstalline Solid
Definition
ChEBI: An N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-ad
inistered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus.
Allgemeine Beschreibung
Although nateglinide, N-(4-isopropylcyclohexanecarbonyl)-D-phenylalanine (Starlix), belongs tothe metaglinides, it is a phenylalanine derivative and representsa novel drug in the management of type 2 diabetes.
Mechanism of action
Approved in the United States in late 2000, nateglinide is a rapidly absorbed insulin secretagogue that has a mechanism of
action similar to that of repaglinide, with effects appearing within 20 minutes following oral dosing.
Bioavailability is 73%,
and it is 98% protein bound, primarily to albumin. Nateglinide is tissue selective, with low affinity for cardiac and skeletal
muscle.
Stoffwechsel
It is metabolized in the liver, with 16% excreted in the urine unchanged. The major metabolites are hydroxyl
derivatives (CYP2C9, 70%; CYP3A4, 30%) that are further conjugated to the glucuronide derivatives.
Nateglinide Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte